Open minded advances in healthcare from wellness innovators Medicaleaf

Over 200 million people in the UK and mainland Europe suffer from debilitating chronic pain, seizures and sleeping disorders as well as an equal number of increasingly enlightened people who can appreciate the recuperative benefit of cannabinoids.

There is a clear movement away from the ‘traditional’ medical practitioners and pharmaceutical companies and we aim to provide trusted and licensed products that can be bought legally and administered safely.

Public awareness and open-mindedness towards alternative cures for lifelong conditions are growing; and the World Health Organization (WHO) reports research suggesting that CBD may have therapeutic benefits for many conditions, including:


• Multiple sclerosis                

• Arthritis

• Spinal cord injury

• Epileptic seizures

• Alzheimer’s disease

• Parkinson’s disease

 

Research is ongoing: clinical trials to test the effectiveness of medicinal cannabis in all its forms will prove best use and lead to more government approved cannabis-based medicinal products (CBMPs) containing cannabidiol (CBD), joining those such as Epidiolex, which is already available on prescription in the UK for the treatment of seizures caused by two severe forms of epilepsy: Lennox- Gastaut syndrome and Dravet syndrome.

Medicaleaf™ was founded by a team of business leaders, marketing & technology experts, scientists, caregivers and advocates who are committed to producing safe, reliable products and promoting wellness from nature.

The widening interest in ‘wellness’ as an alternative, preventative lifestyle, particularly in these times, fuels our fire. As an organisation, we are committed to creating a business that will assist in the alleviation of pain and suffering and collaboratively create products to assist in better wellbeing and healthier living.

Medicaleaf expects to see its valuation increase fivefold before flotation in three years’ time. Medicaleaf are looking to complete their £10 million initial investment by the year end.

Capital raised will be invested in Product Manufacturing, Sales and Marketing campaigns and distribution infrastructure but will also be used for suitable acquisitions and joint ventures that will catapult the growth of the company in suitable strategic moves.

Find Out More about how you can get involved and profit from the £135B European Health and Wellbeing market.

Keep up with the top stories from Reader’s Digest by subscribing to our weekly newsletter.